Literature DB >> 24357668

Clinical findings, pathology, and outcomes of C3GN after kidney transplantation.

Ladan Zand1, Elizabeth C Lorenz1, Fernando G Cosio1, Fernando C Fervenza1, Samih H Nasr2, Manish J Gandhi2, Richard J H Smith3, Sanjeev Sethi4.   

Abstract

C3 glomerulonephritis (C3GN) results from abnormalities in the alternative pathway of complement, and it is characterized by deposition of C3 with absent or scant Ig deposition. In many patients, C3GN progresses to ESRD. The clinical features, pathology, and outcomes of patients with C3GN receiving kidney transplantation are unknown. Between 1996 and 2010, we identified 21 patients at our institution who received a kidney transplant because of ESRD from C3GN. The median age at the time of initial diagnosis of C3GN at kidney biopsy was 20.8 years. The median time from native kidney biopsy to dialysis or transplantation was 42.3 months. Of 21 patients, 14 (66.7%) patients developed recurrent C3GN in the allograft. The median time to recurrence of disease was 28 months. Graft failure occurred in 50% of patients with recurrent C3GN, with a median time of 77 months to graft failure post-transplantation. The remaining 50% of patients had functioning grafts, with a median follow-up of 73.9 months. The majority of patients had hematuria and proteinuria at time of recurrence. Three (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrence and graft loss. Kidney biopsy at the time of recurrence showed mesangial proliferative GN in eight patients and membranoproliferative GN in six patients. All allograft kidney biopsies showed bright C3 staining (2-3+), with six biopsies also showing trace/1+ staining for IgM and/or IgG. To summarize, C3GN recurs in 66.7% of patients, and one half of the patients experience graft failure caused by recurrence.
Copyright © 2014 by the American Society of Nephrology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24357668      PMCID: PMC4005307          DOI: 10.1681/ASN.2013070715

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  16 in total

Review 1.  Membranoproliferative glomerulonephritis--a new look at an old entity.

Authors:  Sanjeev Sethi; Fernando C Fervenza
Journal:  N Engl J Med       Date:  2012-03-22       Impact factor: 91.245

2.  Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.

Authors:  Aude Servais; Véronique Frémeaux-Bacchi; Moglie Lequintrec; Rémi Salomon; Jacques Blouin; Bertrand Knebelmann; Jean-Pierre Grünfeld; Philippe Lesavre; Laure-Hélène Noël; Fadi Fakhouri
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

3.  Recurrence of membranoproliferative glomerulonephritis type II in renal allografts: The North American Pediatric Renal Transplant Cooperative Study experience.

Authors:  Michael C Braun; Don M Stablein; Lorraine A Hamiwka; Lorraine Bell; Sharon M Bartosh; C Frederic Strife
Journal:  J Am Soc Nephrol       Date:  2005-05-11       Impact factor: 10.121

4.  Renal transplantation in patients with dense deposit disease: morphological characteristics of recurrent disease and clinical outcome.

Authors:  M B Andresdottir; K J Assmann; A J Hoitsma; R A Koene; J F Wetzels
Journal:  Nephrol Dial Transplant       Date:  1999-07       Impact factor: 5.992

Review 5.  Membranoproliferative glomerulonephritis and C3 glomerulopathy: resolving the confusion.

Authors:  Sanjeev Sethi; Carla M Nester; Richard J H Smith
Journal:  Kidney Int       Date:  2011-12-07       Impact factor: 10.612

6.  Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association?

Authors:  Frank Bridoux; Estelle Desport; Véronique Frémeaux-Bacchi; Christine Fen Chong; Jean-Marc Gombert; Corinne Lacombe; Nathalie Quellard; Guy Touchard
Journal:  Clin J Am Soc Nephrol       Date:  2011-07-22       Impact factor: 8.237

7.  Recurrent membranoproliferative glomerulonephritis after kidney transplantation.

Authors:  Elizabeth C Lorenz; Sanjeev Sethi; Nelson Leung; Angela Dispenzieri; Fernando C Fervenza; Fernando G Cosio
Journal:  Kidney Int       Date:  2010-02-03       Impact factor: 10.612

8.  Glomeruli of Dense Deposit Disease contain components of the alternative and terminal complement pathway.

Authors:  Sanjeev Sethi; Jeffrey D Gamez; Julie A Vrana; Jason D Theis; H Robert Bergen; Peter F Zipfel; Ahmet Dogan; Richard J H Smith
Journal:  Kidney Int       Date:  2009-01-28       Impact factor: 10.612

Review 9.  New approaches to the treatment of dense deposit disease.

Authors:  Richard J H Smith; Jessy Alexander; Paul N Barlow; Marina Botto; Thomas L Cassavant; H Terence Cook; Santiago Rodriguez de Córdoba; Gregory S Hageman; T Sakari Jokiranta; William J Kimberling; John D Lambris; Lynne D Lanning; Vicki Levidiotis; Christoph Licht; Hans U Lutz; Seppo Meri; Matthew C Pickering; Richard J Quigg; Angelique L Rops; David J Salant; Sanjeev Sethi; Joshua M Thurman; Hope F Tully; Sean P Tully; Johan van der Vlag; Patrick D Walker; Reinhard Würzner; Peter F Zipfel
Journal:  J Am Soc Nephrol       Date:  2007-08-05       Impact factor: 10.121

10.  Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis.

Authors:  S Meri; V Koistinen; A Miettinen; T Törnroth; I J Seppälä
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more
  41 in total

Review 1.  The emerging role of complement inhibitors in transplantation.

Authors:  Véronique Frémeaux-Bacchi; Christophe M Legendre
Journal:  Kidney Int       Date:  2015-09-16       Impact factor: 10.612

Review 2.  C3 Glomerulopathy.

Authors:  Magdalena Riedl; Paul Thorner; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2016-04-07       Impact factor: 3.714

Review 3.  Pathophysiology and management of monoclonal gammopathy of renal significance.

Authors:  Ankur Jain; Richard Haynes; Jaimal Kothari; Akhil Khera; Maria Soares; Karthik Ramasamy
Journal:  Blood Adv       Date:  2019-08-13

Review 4.  Bridging the Divide: An Onco-Nephrologic Approach to the Monoclonal Gammopathies of Renal Significance.

Authors:  Jonathan J Hogan; Brendan M Weiss
Journal:  Clin J Am Soc Nephrol       Date:  2016-07-14       Impact factor: 8.237

Review 5.  Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GN.

Authors:  Maurizio Salvadori; Giuseppina Rosso
Journal:  World J Nephrol       Date:  2016-07-06

Review 6.  Complement cascade and kidney transplantation: The rediscovery of an ancient enemy.

Authors:  Alberto Mella; Maria Messina; Antonio Lavacca; Luigi Biancone
Journal:  World J Transplant       Date:  2014-09-24

7.  C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Authors:  Aishwarya Ravindran; Fernando C Fervenza; Richard J H Smith; Sanjeev Sethi
Journal:  Kidney Int       Date:  2018-05-03       Impact factor: 10.612

Review 8.  Primary disease recurrence—effects on paediatric renal transplantation outcomes.

Authors:  Justine Bacchetta; Pierre Cochat
Journal:  Nat Rev Nephrol       Date:  2015-04-28       Impact factor: 28.314

9.  High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies.

Authors:  Fengxiao Bu; Nicolo Ghiringhelli Borsa; Michael B Jones; Erika Takanami; Carla Nishimura; Jill J Hauer; Hela Azaiez; Elizabeth A Black-Ziegelbein; Nicole C Meyer; Diana L Kolbe; Yingyue Li; Kathy Frees; Michael J Schnieders; Christie Thomas; Carla Nester; Richard J H Smith
Journal:  J Am Soc Nephrol       Date:  2015-08-17       Impact factor: 10.121

10.  C3 glomerulonephritis secondary to mutations in factors H and I: rapid recurrence in deceased donor kidney transplant effectively treated with eculizumab.

Authors:  Neetika Garg; Yuzhou Zhang; Anne Nicholson-Weller; Eliyahu V Khankin; Nicolò Ghiringhelli Borsa; Nicole C Meyer; Susan McDermott; Isaac E Stillman; Helmut G Rennke; Richard J Smith; Martha Pavlakis
Journal:  Nephrol Dial Transplant       Date:  2018-12-01       Impact factor: 5.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.